During the past decade, SPb SBIH "Clinical Rheumatological Hospital # 25" conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 11 clinical trials were completed, i.e. on average, 84.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 8 clinical trials were completed. i.e. 266.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SPb SBIH "Clinical Rheumatological Hospital # 25"" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SPb SBIH "Clinical Rheumatological Hospital # 25"" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Hexal AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "SPb SBIH "Clinical Rheumatological Hospital # 25"" are "Rheumatoid Arthritis" (5 trials), "Systemic Lupus Erythematosus" (3 trials), "Arthritis, Psoriatic" (2 trials), "Axial Spondyloarthritis" (2 trials) and "Active Psoriatic Arthritis" (1 trials). Many other conditions were trialed in "SPb SBIH "Clinical Rheumatological Hospital # 25"" in a lesser frequency.

Most popular intervention types in "SPb SBIH "Clinical Rheumatological Hospital # 25"" are "Drug" (11 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Guselkumab" (2 trials), "Ixekizumab" (2 trials), "Adalimumab" (1 trials) and "Adalimumab - GP2017" (1 trials). Other intervention names were less common.

The vast majority of trials in "SPb SBIH "Clinical Rheumatological Hospital # 25"" are 14 trials for "All" genders.

Currently, there are NaN active trials in "SPb SBIH "Clinical Rheumatological Hospital # 25"". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in SPb SBIH "Clinical Rheumatological Hospital # 25", undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in SPb SBIH "Clinical Rheumatological Hospital # 25", 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".